Posted by on Feb 26, 2019 in Breast cancer | 0 comments

In a nutshell

This trial aims to investigate a new cancer medicine called xentuzumab together with exemestane (Aromasin) and everolimus (Afinitor) in women who have breast cancer that has spread. The main outcome that will be measured is how long the patients go without cancer growing. 

The details

Xentuzumab is a new medication that works by targeting certain molecules on cancer cells. It aims to stop cancer cells from growing. It has not been tested in combination with two other anti-cancer drugs, called everolimus and exemestane.

This trial aims to investigate the effectiveness of xentuzumab combined with everolimus and exemestane in women with advanced breast cancer. The main outcome that will be measured is survival without cancer growing or spreading.

Who are they looking for?

80 post-menopausal women with breast cancer that cannot have curative surgery or radiation. Patients must have adequate organ function.

Patients will not be included if they have a history of lung or heart disease, or if they already received chemotherapy for cancer that has spread, or radiotherapy within 4 weeks prior to the start of study treatment.

How will it work

The patients will be split into two groups. One group will be treated with everolimus and exemestane plus a placebo pill. The second group will be treated with everolimus and exemestane plus xentuzumab. The patients will not know what kind of treatment they are getting. Patients will be followed up to 3 years to evaluate survival without cancer growing and response to treatment.

Clinical trial locations

Locations near 20147, United States (Change):
Please enter zip/postal code and country to help us offer locations near you
Show only recruiting locations
Type:Interventional
Participants:80
Study ID:NCT03659136
Want personalized notifications? Get notified only when trials are matching for you.
(it's free)